A New Modified Experimental Meibomian Gland Injury Model: Partial Loss of Gland Due to Orifice Cauterization and the Alleviating Potential of 22-Oxacalcitriol

A New Modified Experimental Meibomian Gland Injury Model: Partial Loss of Gland Due to Orifice Cauterization and the Alleviating Potential of 22-Oxacalcitriol

1α,-25-dihydroxy-22-oxacalcitriol (maxacalcitol) is a non-calcemic vitamin D3 analog clinically approved to treat psoriasis, and its role has been increasingly recognized in suppressing keratinocyte proliferation, mediating inflammation, and regulating the immune response. A large number of studies...

Full description

Bibliographic Details
Main Authors: Kai Jin, Motoko Kawashima, Masataka Ito, Reiko Arita, Kokoro Sano, Kazuo Tsubota
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Journal of Clinical Medicine
Subjects:
meibomian gland
maxacalcitol
atrophy
ductal dilation
injury model
Online Access:https://www.mdpi.com/2077-0383/10/1/6

Similar Items

Similar Items